This is the authors' abstract. We don't add key points for this paper.
Abstract Background Multiple myeloma is a rising concern globally, with increasing incidence and mortality, especially in low- and middle-income countries. In Saudi Arabia, multiple myeloma care faces significant challenges outside tertiary care centers, including delays in diagnosis, limited availability of standardized treatment protocols, and considerable disparities in healthcare infrastructure. These issues are particularly prominent in non-urban and secondary healthcare facilities, where access to specialized diagnostics and therapies may be restricted, impacting early detection and optimal management of the disease. Summary Although treatment advances have improved survival rates, multiple myeloma remains incurable and poses significant financial burdens due to the high cost of therapies, particularly in resource-constrained settings. This updated guideline from the Saudi Myeloma Working Group aims to address the gaps in newly diagnosed multiple myeloma management in Saudi Arabia. Key messages The guideline provides recommendations on diagnosis, risk stratification, and treatment strategies to optimize care and improve outcomes for patients with multiple myeloma in Saudi Arabia. These recommendations are also relevant to other developing countries facing similar challenges.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Alotaibi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: